Literature DB >> 28197532

Using global gene expression to discriminate thin melanomas with poor outcomes.

Zachary Hothem1, Andrew Bayci1, Bryan J Thibodeau2, Billie E Ketelsen2, Laura E Fortier2, Alison F Uzieblo3, Diane Cosner3, Kristin Totoraitis4, Richard D Keidan1, George D Wilson2.   

Abstract

Most melanomas present as thin lesions (≤1.0 mm) with a good prognosis; however, a small percentage of patients with thin lesions experience recurrence or metastasis. The aim of our study was to identify a distinct pattern of gene expression within thin melanomas known to have eventually metastasized to regional lymph nodes or distant sites compared with those that followed the typical course with good response to wide local excision alone. Patients who were disease-free for a minimum of 10 y served as controls (n = 10) to the experimental group who developed metastasis (n = 9). Laser capture microdissection was used to specifically isolate cancer cells from formalin-fixed paraffin-embedded tissue with subsequent gene expression analysis on Affymetrix Human Transcriptome Array 2.0 Arrays. Although gene expression differences were observed between the patients with thin melanoma with poor clinical outcome and those with good clinical outcome, neither the number of genes nor the magnitude of the fold difference was very substantial or significant. Cluster analysis with this subset of genes could definitively separate a subset of the poor responders from the good responders, but there remained a mixed group of tumors that could not be predicted from gene expression alone. Pathway analysis identified cellular processes that were regulated based on the response, including categories commonly associated with melanoma progression. Ultimately, we concluded that there were very few differences between these groups. Future research will be required and investigation of the mutational landscape may be another strategy to uncover genomic changes that drive recurrence and metastasis in thin melanoma.

Entities:  

Keywords:  Gene expression; melanoma; microarray; surgical response; thin melanoma

Year:  2016        PMID: 28197532      PMCID: PMC5286964          DOI: 10.1080/23723556.2016.1253527

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  34 in total

1.  The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia.

Authors:  F M Benes; D Matzilevich; R E Burke; J Walsh
Journal:  Mol Psychiatry       Date:  2006-03       Impact factor: 15.992

Review 2.  Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.

Authors:  Véronique Winnepenninckx; Joost J van den Oord
Journal:  Expert Rev Anticancer Ther       Date:  2007-11       Impact factor: 4.512

3.  Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.

Authors:  Phyllis A Gimotty; Patricia Van Belle; David E Elder; Todd Murry; Kathleen T Montone; Xiaowei Xu; Susan Hotz; Shane Raines; Michael E Ming; Peter Wahl; Dupont Guerry
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

4.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

5.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

6.  No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report.

Authors:  M Sladden; S Zagarella; C Popescu; M Bigby
Journal:  Br J Dermatol       Date:  2015-03       Impact factor: 9.302

7.  Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.

Authors:  Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

8.  Prediction of survival in patients with thin melanoma: results from a multi-institution study.

Authors:  Andrea Maurichi; Rosalba Miceli; Tiziana Camerini; Luigi Mariani; Roberto Patuzzo; Roberta Ruggeri; Gianfranco Gallino; Elena Tolomio; Gabrina Tragni; Barbara Valeri; Andrea Anichini; Roberta Mortarini; Daniele Moglia; Giovanni Pellacani; Sara Bassoli; Caterina Longo; Pietro Quaglino; Nicola Pimpinelli; Lorenzo Borgognoni; Daniele Bergamaschi; Catherine Harwood; Odysseas Zoras; Mario Santinami
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

Review 9.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  Update on Thin Melanoma: Outcome of an International Workshop.

Authors:  Daniela Mihic-Probst; Chris Shea; Lyn Duncan; Arnaud de la Fouchardiere; Gilles Landman; Jennifer Landsberg; Joost ven den Oord; Lori Lowe; Martin G Cook; Sook Jung Yun; Loren Clarke; Jane Messina; David E Elder; Raymond L Barnhill
Journal:  Adv Anat Pathol       Date:  2016-01       Impact factor: 3.875

View more
  1 in total

1.  Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.

Authors:  Antonio G Richetta; Virginia Valentini; Federica Marraffa; Giovanni Paolino; Piera Rizzolo; Valentina Silvestri; Veronica Zelli; Anna Carbone; Cinzia Di Mattia; Stefano Calvieri; Pasquale Frascione; Pietro Donati; Laura Ottini
Journal:  Oncotarget       Date:  2018-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.